🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What's happening with these clouds? While it may seem that these long and thin clouds are pointing toward the top of a hill, and that maybe a world-famous observatory is located there, only part of that is true. In terms of clouds, the formation is a chance superposition of

In this subanalysis of the #FLOW #RCT presented by Dr Katherine Tuttle at #AHA24, the benefit of #semaglutide in #diabetes w #CKD extended to patients with #CVD Listen to her insights on “the convergence of truth” to “save kidneys, hearts, & lives” #CKM #GLP1RA #DKD

Diabetes and obesity drugs have been found to reduce the risk of kidney failure and protect cardiovascular health in people with and without diabetes. New research by Sunil Badve and Vlado Perkovic published today 👇 bit.ly/3AUAKXB

Popular diabetes drugs like Ozempic can reduce the risk of kidney failure and death due to kidney or cardiovascular causes in people with and without diabetes, new research from Sunil Badve and Vlado Perkovic shows. The George Institute for Global Health bit.ly/3Zru4K4

New—Effects of #GLP-1 receptor agonists on #kidney and #cardiovascular disease outcomes: a meta-analysis of randomised controlled trials thelancet.com/journals/landi… #T2D #CVD

Clear reductions in all outcomes with GLP-1RA: Kidney failure ✅ Major CV events ✅ Heart failure ✅ CV death ✅ All-cause death ✅ Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes Now in The Lancet Diabetes & Endocrinology thelancet.com/journals/landi…

📢 #GLP1 receptor agonists improve both kidney- and heart-related clinical outcomes for individuals with: ▶️ #type2diabetes ▶️ #chronickidneydisease ▶️ #overweight and #obesity Nephrology News & Issues Cardiology Today The Lancet Diabetes & Endocrinology Sunil Badve The George Institute for Global Health healio.com/news/endocrino…

#ICYMI: GLP-1 RA with and without SGLT2i Muthu Vaduganathan Sunil Badve Richard Pratley MD @lheath Brendon Neuen

Five fielders and the wicket keeper are wearing a helmet. Must be a record. #INDvsAUS

A randomized controlled trial evaluated the efficacy and safety of #apixaban for prevention of recurrent thrombosis after #thrombectomy of #hemodialysis #vascularaccess doi.org/10.1016/j.kint…

Lauren R. Sorce Sebastian Palmqvist Niklas Mattsson-Carlgren Jan De Waele MD Toby Maher Alex Spyropoulos Most Viewed JAMA 2024: Medications for Obesity 🔗 ja.ma/3Djs3ab Dr Robert Kushner

Evidence is thin that hypertension causes chronic kidney disease. academic.oup.com/ndt/advance-ar…

Cardiovascular, Kidney & Mortality Outcomes With Injectable & Oral GLP1-RA in T2 Diabetes An updated meta-analysis of >70,000 patients after the SOUL trial by Matthew MY Lee et al. ⬇️ 14% MACE ⬇️ 14% heart failure ⬇️ 17% CKD ⬇️ 12% all-cause mortality diabetesjournals.org/care/article/d…

In SOUL, 2596/9650 (26.9%) participants were receiving SGLT2i at baseline (largest CVOT of combined GLP-1/SGLT2 to date) The effect of oral semaglutide on cardiovascular outcomes was consistent, regardless of SGLT2i use #ACC25 ahajournals.org/doi/abs/10.116…

Save the date for Kidney Supportive Care Masterclass 2025 and Serious Illness Conversations Workshop. Open to nephrologists, nephrology trainees and nurse practitioners. Separate registrations for the Masterclass (forms.office.com/r/L90B6DrscS) and the Workshop (email in the image).